IN2013MN01438A - - Google Patents

Download PDF

Info

Publication number
IN2013MN01438A
IN2013MN01438A IN1438MUN2013A IN2013MN01438A IN 2013MN01438 A IN2013MN01438 A IN 2013MN01438A IN 1438MUN2013 A IN1438MUN2013 A IN 1438MUN2013A IN 2013MN01438 A IN2013MN01438 A IN 2013MN01438A
Authority
IN
India
Prior art keywords
heavy chains
covalent link
identical heavy
region
fab region
Prior art date
Application number
Other languages
English (en)
Inventor
Itai Benhar
Lilach Vaks
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot filed Critical Univ Ramot
Publication of IN2013MN01438A publication Critical patent/IN2013MN01438A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
IN1438MUN2013 2011-03-17 2012-03-15 IN2013MN01438A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161453591P 2011-03-17 2011-03-17
PCT/IL2012/050093 WO2012123949A1 (en) 2011-03-17 2012-03-15 Bi- and monospecific, asymmetric antibodies and methods of generating the same

Publications (1)

Publication Number Publication Date
IN2013MN01438A true IN2013MN01438A (pt) 2015-06-12

Family

ID=45999923

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1438MUN2013 IN2013MN01438A (pt) 2011-03-17 2012-03-15

Country Status (11)

Country Link
US (2) US9624291B2 (pt)
EP (1) EP2686348B1 (pt)
JP (1) JP2014510084A (pt)
KR (1) KR20140019385A (pt)
CN (1) CN103429619B (pt)
AU (1) AU2012227883A1 (pt)
BR (1) BR112013023653A2 (pt)
CA (1) CA2827188C (pt)
IN (1) IN2013MN01438A (pt)
MX (1) MX342135B (pt)
WO (1) WO2012123949A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
CN103025884B (zh) 2010-07-26 2015-11-25 特里安尼公司 转基因动物和使用方法
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
CN103429619B (zh) 2011-03-17 2017-07-28 雷蒙特亚特特拉维夫大学有限公司 双特异性和单特异性、不对称抗体和其制备方法
US9465889B2 (en) * 2012-07-05 2016-10-11 Physion Consulting, LLC Method and system for identifying data and users of interest from patterns of user interaction with existing data
CA2892059C (en) 2012-11-21 2023-02-14 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody
NZ710422A (en) * 2013-01-24 2016-11-25 Scripps Korea Antibody Inst Protein combination-based fv library, and preparation method therefor
MX2015010438A (es) * 2013-02-15 2016-05-05 Pharm Cjsc Closed Joint Stock Company R COMPOSICION DE INHIBIDOR DE IL-1ß Y USO DE LA MISMA.
AU2014230291B2 (en) 2013-03-13 2018-02-22 Ibentrus, Inc. Protein in which electrical interaction is introduced within hydrophobic interaction site and preparation method therefor
IL302303A (en) 2013-12-17 2023-06-01 Genentech Inc Anti-CD3 antibodies and methods of using them
US10822399B2 (en) 2014-02-10 2020-11-03 Igm Biosciences, Inc. IgA multi-specific binding molecules
JP6447887B2 (ja) * 2014-03-03 2019-01-09 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 二重特異性抗体及びその使用
WO2015153765A1 (en) 2014-04-01 2015-10-08 Adimab, Llc Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
BR112016024780A2 (pt) * 2014-05-02 2017-10-10 Momenta Pharmaceutical Inc composições e métodos relacionados com construtos de fc manipulados
US9884921B2 (en) 2014-07-01 2018-02-06 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
EP3222637A4 (en) * 2014-11-21 2018-10-31 Astellas Pharma Inc. Novel bispecific antibody format
WO2016204966A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Anti-cd3 antibodies and methods of use
CN108138200A (zh) * 2015-08-24 2018-06-08 特里安尼公司 增强的免疫球蛋白产生
EP3356403A2 (en) * 2015-10-02 2018-08-08 H. Hoffnabb-La Roche Ag Bispecific antibodies specific for a costimulatory tnf receptor
US10813346B2 (en) 2015-12-03 2020-10-27 Trianni, Inc. Enhanced immunoglobulin diversity
WO2017136734A1 (en) 2016-02-04 2017-08-10 Trianni, Inc. Enhanced production of immunoglobulins
EP3484514B1 (en) 2016-05-23 2023-12-06 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
WO2017205014A1 (en) 2016-05-26 2017-11-30 Qilu Puget Sound Biotherapeutics Corporation Mixtures of antibodies
US20200071382A1 (en) * 2016-07-07 2020-03-05 Acceleron Pharma Inc. Tgf-beta superfamily heteromultimers and uses thereof
EP3489262A4 (en) 2016-07-19 2020-07-08 Ibentrus, Inc. SPECIFIC PROTEINS AND METHOD FOR THE PRODUCTION THEREOF
CN106496331B (zh) * 2016-11-08 2020-03-13 北京智岭生物医药科技有限公司 一种FSH-Fc融合蛋白及其制备方法和用途
WO2018089293A2 (en) 2016-11-08 2018-05-17 Qilu Puget Sound Biotherapeutics Corporation Anti-pd1 and anti-ctla4 antibodies
KR20190074300A (ko) 2016-11-15 2019-06-27 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
WO2018129255A1 (en) 2017-01-06 2018-07-12 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
CN111712261A (zh) 2018-02-08 2020-09-25 豪夫迈·罗氏有限公司 双特异性抗原结合分子和使用方法
TW202016151A (zh) 2018-06-09 2020-05-01 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
US20220089722A1 (en) * 2018-12-29 2022-03-24 Nantong Yichen Biopharma. Co. Ltd. Heterodimeric fusion protein
US11845799B2 (en) 2019-12-13 2023-12-19 Genentech, Inc. Anti-Ly6G6D antibodies and methods of use
CN113480645B (zh) * 2021-07-16 2022-11-11 甘肃中科博瑞生物工程有限公司 一种抗幽门螺旋杆菌重组抗体、制备方法及用途
WO2023201291A1 (en) 2022-04-13 2023-10-19 Genentech, Inc. Pharmaceutical compositions of mosunetuzumab and methods of use
CN116789836B (zh) * 2023-08-14 2024-01-05 浙江时迈药业有限公司 针对dll3的抗体及其用途

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6037137A (en) 1997-02-20 2000-03-14 Oncoimmunin, Inc. Fluorogenic peptides for the detection of protease activity
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
CA2527694C (en) * 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Fab library for the preparation of anti vegf and anti rabies virus fabs
US7655229B2 (en) * 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
JP2008523105A (ja) * 2004-12-14 2008-07-03 エンゾン ファーマシューティカルズ，インコーポレーテッド ポリマー連結シュードモナス外毒素免疫毒素
WO2008020823A2 (en) * 2005-05-23 2008-02-21 University Of Hawaii Cooperative reporter systems, components, and methods for analyte detection
WO2009036209A2 (en) * 2007-09-14 2009-03-19 Amgen Inc. Homogeneous antibody populations
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
JP2011514161A (ja) 2008-02-29 2011-05-06 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド 免疫グロブリン組成物およびその製造方法
CN102643345A (zh) * 2008-09-26 2012-08-22 罗氏格黎卡特股份公司 双特异性抗-egfr/抗-igf-1r抗体
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
JP4694610B2 (ja) 2008-10-30 2011-06-08 シャープ株式会社 承認者決定装置及び当該承認者決定装置を有するファクシミリ装置
CA2756244A1 (en) * 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
CA2757931C (en) 2009-04-07 2019-03-26 Roche Glycart Ag Trivalent, bispecific antibodies
MX2011010158A (es) * 2009-04-07 2011-10-17 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-2/anti-c-met.
US8796759B2 (en) 2010-07-15 2014-08-05 Taiwan Semiconductor Manufacturing Company, Ltd. Fin-like field effect transistor (FinFET) device and method of manufacturing same
CN103429619B (zh) 2011-03-17 2017-07-28 雷蒙特亚特特拉维夫大学有限公司 双特异性和单特异性、不对称抗体和其制备方法

Also Published As

Publication number Publication date
CA2827188A1 (en) 2012-09-20
US20140010814A1 (en) 2014-01-09
US10822428B2 (en) 2020-11-03
WO2012123949A8 (en) 2013-03-14
KR20140019385A (ko) 2014-02-14
JP2014510084A (ja) 2014-04-24
BR112013023653A2 (pt) 2016-12-13
US20170174791A1 (en) 2017-06-22
MX342135B (es) 2016-09-14
CN103429619A (zh) 2013-12-04
US9624291B2 (en) 2017-04-18
AU2012227883A8 (en) 2013-11-07
WO2012123949A1 (en) 2012-09-20
CA2827188C (en) 2020-02-11
EP2686348B1 (en) 2015-12-30
EP2686348A1 (en) 2014-01-22
MX2013010590A (es) 2014-05-27
CN103429619B (zh) 2017-07-28
AU2012227883A1 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
IN2013MN01438A (pt)
PH12014501783B1 (en) Anti-lipoarabinomannan antibody and immunoassay for acid-fast bacillary infection using the antibody
MX356288B (es) Anticuerpos biespecificos igg4 modificados de secuencia simetrica.
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
NZ703653A (en) Anti-fap antibodies and methods of use
CY1121832T1 (el) Μονοκλωνικα αντισωματα κατα του παραγοντα αναπτυξεως και διαφοροποιησεως 15(gdf-15)
PE20171103A1 (es) Anticuerpos heterodimericos que se unen a cd3 y cd38
MX356947B (es) Anticuerpos bioespecíficos específicos para antígenos que activan células t y un antígeno tumoral y métodos de uso.
PE20150002A1 (es) Anticuerpos anti-fcrn
NZ701040A (en) Covalently linked antigen-antibody conjugates
IN2014DN10428A (pt)
NZ629296A (en) Humanized antibodies that recognize alpha-synuclein
NZ631098A (en) Anti-hepcidin antibodies and uses thereof
CY1115030T1 (el) Διειδικα αντι-vegf/αντι-ang-2 αντισωματα
MX344040B (es) Anticuerpos mejorados de la clase inmonoglubina g4 (igg4).
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
UY34394A (es) Polipéptidos de anticuerpos que antagonizan cd40l
NZ626269A (en) Anti-phf-tau antibodies and their uses
WO2014012085A3 (en) Bispecific asymmetric heterodimers comprising anti-cd3 constructs
MX2014001799A (es) Anticuerpos sin fc qie comprenden dos fragmentos fab y metodos de uso.
NZ720765A (en) Antibodies and methods of use
NZ726258A (en) Antibodies and uses thereof to detect folate receptor 1
EA201391292A1 (ru) Способ получения подложки, обеспеченной покрытием
MX2015000681A (es) Metodo para producir receptores de fc (fcr) solubles como fusion de fc con region de fc de inmunoglobulina inerte y uso de las mismas.
NZ616382A (en) Antibodies specific to cadherin-17